Bupivacaine Hydrochloride/Epinephrine Bitartrate

盐酸布比卡因/重酒石酸肾上腺素

Report date: 2025/09/26 16:39:26

Base Information

Drug NameBupivacaine Hydrochloride/Epinephrine Bitartrate
Drug Alias Name重酒石酸肾上腺素/盐酸布比卡因Epinephrine Bitartrate/Bupivacaine HydrochlorideMarcaine
ClassificationSmall molecules
Mechanisms of ActionSodium channel alpha subunit blockersBeta adrenergic receptors agonistsAdrenergic receptor alpha-1 agonists
TargetsSodium channel alpha subunitBeta adrenergic receptorsAdrenergic receptors alpha-1
Therapy Area/IndicationsFractures, BonePain, PostoperativeNervous System Diseases +[4] 
Global Approved IndicationsPain, PostoperativeAnesthesia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1972/10/03
Country/TerritoryUnited States
CombinationsYes Epinephrine BitartrateBupivacaine Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHospira Inc
China Registration ClassN/A

Develop Information

Active CompaniesHospira IncAssiut University
Inactive CompaniesUniversity Of Southern California
Active IndicationsPain, PostoperativeNervous System DiseasesAnesthesia
Inactive IndicationsFractures, Bone

Other Information

ATC CodeN01
Related LinksN/A